September 26, 2018   
Gillette Stadium

<< Back to Agenda

Women in Pharma® (WIP) Event

All are welcome to attend the first-ever Women in Pharma® (WIP) event at the Product Show from 2:00 – 3:30 pm! Join us in Red Level Suite 81 (one level above the show floor) as we discuss the future of the Chapter’s WIP program, enjoy networking opportunities, and hear from special guest Dr. Trish Hurter, Senior Vice President, Pharmaceutical & Preclinical Sciences at Vertex Pharmaceuticals.

Join us and leave your business card for a chance to win a special gift basket created by WIP volunteer, Tina Smith!

About Dr. Trish Hurter: 

Trish Hurter is a senior pharmaceutical executive who has contributed to four breakthrough drugs and conceived and executed the first FDA-approved continuous manufacturing facility in the world. Dr. Hurter brings a multifaceted background in drug discovery and development, including Preclinical & Pharmaceutical Development, Project Management, Regulatory Affairs, and GMP Manufacturing. She has been instrumental in the development of several approved therapies, namely Januvia, Incivek, Kalydeco, Orkambi, and Symdeko.

Dr. Hurter serves as Senior Vice President, Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals where she has held various management positions with increasing responsibility since 2004. She currently manages a diverse group of ~320 scientific and operational professionals fully accountable for all CMC and preclinical development, including early discovery through commercialization. Dr Hurter’s scope includes an internal GMP manufacturing facility, which manufactures clinical trial materials as well as commercial drug product using a state of the art continuous manufacturing line. Dr. Hurter is the founder and executive sponsor of “IWILL”, a Vertex employee resource network devoted to the advancement of women leaders.

From 2013-2014, Dr. Hurter led Global Regulatory Affairs at Vertex. Vertex’s global applications for several label expansions for Kalydeco received FDA approval on her watch, and a new drug application for the breakthrough cystic fibrosis therapy, Orkambi, was filed in the US and Europe, and subsequently approved.

Prior to joining Vertex, Dr. Hurter was Director, Formulation Design and Characterization for Merck. Before joining the pharmaceutical industry, Dr. Hurter worked in the paper industry for 8 years studying the microstructure of paper and its effect on end use performance, and founded a consulting practice specializing in statistical design of experiments.

A PhD graduate in Chemical Engineering from MIT, Dr. Hurter also received an M.S. in Mechanical Engineering from West Virginia University as well a BScChemEng cum laude from the University of KwaZulu Natal, in Durban, South Africa. An avid equestrian, Dr. Hurter competes actively in show-jumping and lives in Harvard, Massachusetts with her husband and two children.